{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"CD8 levels will be correlated with PD-L1 expression using Pearson or Spearman rank correlation coefficients.","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.\n\nPembrolizumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacogenomic Study: Correlative studies","id":"OG000","title":"Treatment (Pembrolizumab)"}],"populationDescription":"Exploratory endpoint. Data not collected.","reportingStatus":"POSTED","timeFrame":"Baseline","title":"CD8 TILs Will be Assessed by Percentage of Tumor Showing Infiltration","type":"OTHER_PRE_SPECIFIED"}